Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded rights position Tenax to engage potential global strategic pharmaceutical partners Improved net sales royalty rate structure, now ranging from high single-digit to low-teen percentages.

与猎户座公司（Orion Corporation）签订的现有独家许可协议修正案将Tenax在北美的领土权利扩大到了全球范围扩大了Tenax与潜在的全球战略制药合作伙伴的权利地位改进了净销售版税率结构，现在从高个位数到低青少年百分比不等。

Lowered maximum cost of goodsModified milestone provisions, including additional payment for regulatory approval in Japan, reflect multi-billion dollar global PH-HFpEF opportunityNeurological indications excluded from Tenax’s right of first negotiation to commercialize new applications of levosimendan developed by Orion CHAPEL HILL, N.C., Feb.

降低了商品修改里程碑条款的最高成本，包括日本监管部门批准的额外费用，反映了数十亿美元的全球PH HFpEF机会神经系统适应症被排除在Tenax首次谈判的权利之外，以商业化由北卡罗来纳州猎户座教堂山开发的左西孟旦的新应用。

20, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

2024年2月20日（环球通讯社）--Tenax Therapeutics，Inc.（纳斯达克：TENX），一家三期开发阶段的制药公司，专注于识别、开发和商业化产品，以解决心血管和肺部疾病以及高度未满足的医疗需求，今天宣布它已确保全球发展、商业，口服和皮下左西孟旦治疗射血分数保留的心力衰竭肺动脉高压（PH-HFpEF）的知识产权。

“We are delighted to enter into this important amendment to our license from Orion. We have achieved a key corporate objective by expanding our development, IP, and commercial territory rights for levosimendan beyond North America,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.

Tenax Therapeutics总裁兼首席执行官克里斯·佐丹诺（ChrisGiordano）表示：“我们很高兴对Orion的许可证进行这项重要修订。我们通过将左西孟旦的开发、知识产权和商业领域权利扩展到北美以外，实现了一个关键的公司目标。”。

“By gaining these worldwide rights, we are now positioned to realize a much larger share of this unique and exciting cardiovascular medicine’s value, including through the possible establishment of a global strategic alliance.” To further maximize the value of these new global commercial rights, Tenax cont.

“通过获得这些全球权利，我们现在可以实现这种独特而令人兴奋的心血管医学价值的更大份额，包括通过可能建立的全球战略联盟。”为了进一步最大化这些新的全球商业权利的价值，Tenax cont。